Diphenylhydantoin: correlation between protein binding and albumin concentration. 1975

R Gugler, and D L Azarnoff, and D W Shoeman

The unbound fraction of diphenylhydantoin is inversely correlated with the patient's serum albumin concentration and can be accurately estimated graphically without binding analyses. The data for this relationship was obtained from a study in which we observed that the unbound fraction of diphenylhydantoin was two times higher in patients with the nephrotic syndrome. However, in these patients it was not necessary to diminish the dosage since the absolute concentration of unbond drug was unchanged due to a compensatory increase in the apparent volume of distribution and plasma clearance.

UI MeSH Term Description Entries
D009404 Nephrotic Syndrome A condition characterized by severe PROTEINURIA, greater than 3.5 g/day in an average adult. The substantial loss of protein in the urine results in complications such as HYPOPROTEINEMIA; generalized EDEMA; HYPERTENSION; and HYPERLIPIDEMIAS. Diseases associated with nephrotic syndrome generally cause chronic kidney dysfunction. Childhood Idiopathic Nephrotic Syndrome,Frequently Relapsing Nephrotic Syndrome,Multi-Drug Resistant Nephrotic Syndrome,Pediatric Idiopathic Nephrotic Syndrome,Steroid-Dependent Nephrotic Syndrome,Steroid-Resistant Nephrotic Syndrome,Steroid-Sensitive Nephrotic Syndrome,Multi Drug Resistant Nephrotic Syndrome,Nephrotic Syndrome, Steroid-Dependent,Nephrotic Syndrome, Steroid-Resistant,Nephrotic Syndrome, Steroid-Sensitive,Nephrotic Syndromes,Steroid Dependent Nephrotic Syndrome,Steroid Resistant Nephrotic Syndrome,Steroid Sensitive Nephrotic Syndrome,Steroid-Dependent Nephrotic Syndromes,Steroid-Resistant Nephrotic Syndromes,Steroid-Sensitive Nephrotic Syndromes,Syndrome, Nephrotic,Syndrome, Steroid-Sensitive Nephrotic
D010672 Phenytoin An anticonvulsant that is used to treat a wide variety of seizures. It is also an anti-arrhythmic and a muscle relaxant. The mechanism of therapeutic action is not clear, although several cellular actions have been described including effects on ion channels, active transport, and general membrane stabilization. The mechanism of its muscle relaxant effect appears to involve a reduction in the sensitivity of muscle spindles to stretch. Phenytoin has been proposed for several other therapeutic uses, but its use has been limited by its many adverse effects and interactions with other drugs. Diphenylhydantoin,Fenitoin,Phenhydan,5,5-Diphenylhydantoin,5,5-diphenylimidazolidine-2,4-dione,Antisacer,Difenin,Dihydan,Dilantin,Epamin,Epanutin,Hydantol,Phenytoin Sodium,Sodium Diphenylhydantoinate,Diphenylhydantoinate, Sodium
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012709 Serum Albumin A major protein in the BLOOD. It is important in maintaining the colloidal osmotic pressure and transporting large organic molecules. Plasma Albumin,Albumin, Serum

Related Publications

R Gugler, and D L Azarnoff, and D W Shoeman
May 1975, Archives of neurology,
R Gugler, and D L Azarnoff, and D W Shoeman
January 1974, Transactions of the American Neurological Association,
R Gugler, and D L Azarnoff, and D W Shoeman
January 1970, Acta pharmacologica et toxicologica,
R Gugler, and D L Azarnoff, and D W Shoeman
October 1975, The Journal of pharmacology and experimental therapeutics,
R Gugler, and D L Azarnoff, and D W Shoeman
February 2019, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy,
R Gugler, and D L Azarnoff, and D W Shoeman
January 1970, Acta pharmacologica et toxicologica,
R Gugler, and D L Azarnoff, and D W Shoeman
March 1966, The Journal of clinical endocrinology and metabolism,
R Gugler, and D L Azarnoff, and D W Shoeman
December 1973, Biochemical pharmacology,
R Gugler, and D L Azarnoff, and D W Shoeman
January 1987, Hepatology (Baltimore, Md.),
R Gugler, and D L Azarnoff, and D W Shoeman
November 1998, The American journal of gastroenterology,
Copied contents to your clipboard!